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Abstract 
Cytomedical therapy for human interleukin-6 transgenic mice (hlL-6 Tgm) was implemented by the intraperitoneal 
injection of alginate-poly(L)lysine-alginate (APA) membranes microencapsulating SK2 hybridoma cells (APA-SK2 cells) 
which secrete anti-hlL-6 monoclonal antibodies (SK2 mAb). IgG1 plasmacytosis in the hlL-6 Tgm was suppressed by a 
single injection of APA-SK2 cells, and the survival time of these mice was remarkably prolonged. The viable cell number 
and the SK2 mAb-secretion of APA-SK2 cells increased for at least one month both under culture conditions and in 
allogeneic recipients (in vivo). Moreover, SK2 mAb which were secreted from APA-SK2 cells injected into allogeneic 
recipients was detected in serum at high concentrations; 3-5 mg/ml from day 14 to day 50 post-injection. In contrast, he 
injection of free SK2 cells had no therapeutic effect on hlL-6 Tgm. These results strongly suggest that APA membranes 
microencapsulating cells which were modified to secrete molecules useful for the treatment of a disorder were effective as 
an in vivo long-term delivery system of bioactive molecules, as 'cytomedicine'. 
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1. Introduction 
Cell therapy using microencapsulated cells or tis- 
sues has been extensively studied by many re- 
searchers. The microencapsulation of living cells or 
tissues has some advantages as an in vivo delivery 
system for hormones, enzymes and other 
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biomolecules, because the physiological release of 
secretory products from the immobilized cells can 
last for a long time owing to the presence of a 
physical, semipermeable barrier between the trans- 
planted cells or tissues and the host's immune sys- 
tem. This treatment method is applicable to bioartifi- 
cial organs, somatic gene therapy and drug delivery 
systems for biologically active molecules. Bioartifi- 
cial organs, i.e., the transplantation f cells or tissues 
(such as islets of Langerhans [5-7], hepatocytes 
[11,12], parathyroid cells [13-15], pituitary cells [16- 
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18] and thymic epithelial cells [19]) which are en- 
closed in a semipermeable membrane, has been pro- 
posed as an alternative to hormone and enzyme re- 
placement therapy. With the development of genetic 
engineering and cell technology, cell therapy using 
modified universal cell lines which produce and se- 
crete biologically active molecules has been applied 
to a wide variety of disorders including Parkinson's 
disease [20-25], Alzheimer disease [26-28], amy- 
otrophic lateral sclerosis [29], adenosine deaminase 
deficiency [30], hemophilia B [31] and dwarfism 
[32-35]. 
We have previously reported an in vivo long-term 
drug delivery system for biologically active 
molecules, which we named 'cytomedicine' [36]. We 
demonstrated that IgG1 plasmacytosis and 
mesangio-proliferative glomerulonephritis in human 
interleukin 6 transgenic mice (hIL-6 Tgm) were im- 
proved by intraperitoneal injection of SK2 cells, 
which produce and secrete anti-hIL-6 monoclonal 
antibodies (SK2 mAb; mouse IgG1), entrapped in 
agarose microbeads (Aga-SK2 cells). However, the 
therapeutic effects were unfortunately reduced after 
day 50 post-injection of the Aga-SK2 cells, probably 
because the Aga-SK2 cells failed to remain vital for 
longer than that in the allogeneic recipients. There- 
fore, in order to prolong the therapeutic effect of this 
system (cytomedicine), we searched for an alternative 
to agarose hydrogel as a polymer for cell microen- 
capsulation. The polymer for cell microencapsulation 
must have the following properties; (1) selective per- 
meability of nutrients, oxygen, and cellular metabo- 
lites such as lactate, (2) immunoisolation f the trans- 
planted cells or tissues from the host's cellular- and 
humoral-mediated graft rejection, (3) strength resis- 
tant to the procedure of injection, (4) entrapment of
cells for a long time without he leakage of cells, (5) 
no toxicity to the microencapsulated cells and the 
recipient. We selected a biocompatible, semiperme- 
able and durable alginate-poly(L)lysine-alginate 
(APA) microcapsular membrane which was devel- 
oped by Sun et al. [8-10,13,14,32] and has all of the 
above properties. 
The APA membrane is formed by inteffacial poly- 
condensation between poly-L-lysine solution and cal- 
cium alginate beads. The APA membrane provides 
the cells with an immunoisolated nvironment, be- 
cause it has a selective semipermeable characteristic 
that allows small molecules such as glucose and 
nutrients to diffuse freely through the membrane but 
prevents the passage of large molecules and cells. 
The parameters affecting the size, shape and mem- 
brane molecular weight cut-off of the APA microcap- 
sule have been largely defined by Goosen et al. 
[37-39]. We speculated that the APA microcapsules 
would have a large inner space for cell proliferation 
as compared with agarose microbeads. 
In this study we examined the therapeutic effects 
of SK2 cells encapsulated in APA membranes (APA- 
SK2 cells) on IgG1 plasmacytosis n hIL-6 Tgm. 
Moreover, the serum concentrations of SK2 mAb 
secreted from the APA-SK2 cells and the growth 
profile of APA-SK2 cells were evaluated in allo- 
geneic recipients. 
2. Materials and methods 
2.1. Animals 
C57BL/6 mice (female, 5 weeks old) and 
BALB/c mice (female, 5 weeks old) were purchased 
from the Shimizu Experimental Animal Co., Kyoto, 
Japan. The hIL-6 Tgm were kindly provided by Dr. 
T. Kishimoto (Osaka University Medical School, Os- 
aka, Japan) and produced as described previously 
[40-42]. 
2.2. Cells 
SK2 cells that produce and secrete SK2 mAb were 
established as previously described [43] and main- 
tained by intraperitoneal serial passage in BALB/c 
mice which were intraperitoneally injected with 0.5 
ml of pristane (2,6,10,14-tetramethylpentadecane; 
Wako Pure Chemical Co., Osaka) 1 week before the 
inoculation of cells. MH60 cells that proliferate in an 
IL-6 dose-dependent manner [44] were cultured in 
RPMI 1640 medium (Nissui Seiyaku Co., Tokyo, 
Japan) supplemented with 10% fetal calf serum (FCS), 
5 × 10 -5 M of 2-mercaptoethanol (Wako) and 200 
pg/ml  of hIL-6 at 37°C in 5% CO 2. 
2.3. Antibodies 
SK2 mAb were purified from ascites of BALB/c 
mice injected with SK2 cells with a Protein G Seph- 
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arose ® 4 Fast Flow column (Pharmacia Biotech, 
Tokyo). 
2.4. Microencapsulation f SK2 cells within the APA 
membrane 
The microencapsulation f SK2 cells within the 
APA membrane was performed by the method of Sun 
et al. [ 1-4,9,10,32] with minor modifications. Briefly, 
SK2 cells were suspended with 1.8 wt% sodium 
alginate (Kelton LVCR®; Kelco Division of Merck 
and Co., San Diego, CA) solution, which was steril- 
ized with membrane filter of pore size 0.2 /zm, at the 
final cell concentration of 1 X 10 6 or 5 X 10 6 
cells/ml. This cell suspension was extruded through 
a 24-gauge needle with an air jet into a 1.5 wt% 
CaC12 solution. In this step, Ca 2+ is cross-linked to 
the surface layer of the polysaccharide polymers. 
Then the calcium alginate gel beads containing SK2 
cells were suspended with 0.1 wt% poly(L)lysine 
(MW 15 000-30 000; Sigma Chemical Co., St. Louis, 
MO) solution for 10 min to cross-link the negatively 
charged surface of the beads with a polycation. After 
washing three times with saline, the microbeads were 
suspended with 0.03 wt% sodium alginate solution 
for 4 rain. In order to make the membrane thicker, 
the microbeads were resuspended with 0.1 wt% 
poly(L)lysine solution again and then with 0.03 wt% 
sodium alginate solution with same protocol de- 
scribed above. After washing three times with saline, 
the microbeads were suspended with 55 mM sodium 
citrate solution for 5 min, and then washed several 
times with saline to remove excess citrate and lique- 
fied alginate, resulting in the APA microcapsules. 
The APA microcapsules had diameters of 400-600 
/.zm. 
2.5. Microencapsulation of SK2 cells with agarose 
hydrogel 
SK2 cells were microencapsulated in agarose beads 
as described previously [36,45,46]. 
2.6. Eualuation of proliferation and SK2 mAb-secre- 
tion of APA-SK2 cells 
APA-SK2 cells (1 X 10 6 cells per ml of capsules) 
were cultured in RPMI 1640 medium supplemented 
with 10% FCS at 37°C in 5% CO 2 (in vitro) or 
intraperitoneally injected in C57BL/6 mice (in vivo). 
The viable cell number of APA-SK2 cells recovered 
from culture dishes and from the peritoneal cavities 
of mice, respectively, were measured by 3-(4,5-di- 
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT; Dojindo, Kumamoto, Japan) assay according 
to the method described by Mosmann [47]. Briefly, 
200 /xl of MTT solution (5 mg/ml)  was added to 
24-well culture plates containing 100 /zl recovered 
APA microcapsules in 2 ml tissue culture medium 
and incubated at 37°C for 4 h. MTT containing 
medium was removed by vacuum aspiration, and the 
APA microcapsules were washed with Ca2+-Mg 2+- 
free Dulbecco's phosphate-buffered saline [PBS(-  )]. 
The resultant formazan product was dissolved in 400 
/xl of 10% sodium dodecyl sulfate (SDS; 
Wako)/0.005 N HC1 by vortexing. 100 /zl of the 
solution was transferred to a 96-well microplate and 
read on a microplate reader at 595 nm test wave- 
length with the reference of 655 nm. 
The amount of production of SK2 mAb from the 
APA-SK2 cells recovered from the culture dishes or 
peritoneal cavities of mice was measured with a 
mouse IgGl-enzyme-linked immunosorbent assay 
(mlgG1-ELISA) system, using the conditioned 
medium with which 200 /~1 of APA-SK2 cells were 
cultured for 24 h. 
2.7. Therapeutic treatment of hlL-6 Tgm 
As shown in Fig. 1, 3 ml of APA-SK2 cells 
(5 X 10 6 cells per ml of capsules) or Aga-SK2 cells 
(1.25 × 107 cells per ml of beads) in PBS( - )  or 500 
/zl of unmicroencapsulated SK2 cell suspension (free 
SK2 cells; 7.5 X l07 cells/ml) in PBS( - )  was i.p. 
injected with an 18-gauge needle into hIL-6 Tgm (7 
weeks old). In another experiment, 50 /zg of SK2 
mAb was injected s.c. in hIL-6 Tgm (3 t imes/week 
between 7 and 13 weeks of age). Untreated hIL-6 
Tgm or littermates were used as control group or 
normal group, respectively. Each of these six groups 
was comprised of at least 4 mice. 
2.8. Measurement ofplasma lgG1 concentration and 
spleen weight 
IgG1 plasmacytosis was evaluated by plasma IgG1 
level and spleen weight. The IgG1 level in plasma 
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was measured with the mlgG1-EL ISA .  B lood sam- 
ples were recovered f rom the tail vein of  the mice. 
Spleen weight was measured at 14 weeks  old and 
evaluated by using Student 's  t-test. 
3. Resu l t s  
3.1. Growth profile and SK2 mAb-secretion of cul- 
tured APA-SK2 cells 
2.9. Measurement of serum SK2 mAb concentration 
in C57BL/6  mice injected with APA-SK2 cells 
The serum of C57BL/6 mice injected with APA- 
SK2 cells (1 X 10 6 cells per ml of capsules) or free 
SK2 cells in the same protocol described above for 
the hIL-6 Tgm was prepared from blood samples 
recovered from the tail vein. MH60.BSF2, an IL-6- 
dependent murine hybridoma clone [44], was seeded 
in a 96-well culture plate at a concentration f 5 X 103 
cells/100 /zl/well with 4 pg/ml  hIL-6 and test 
sample or standard SK2 mAb, and cultured for 68 h. 
Then, 10/zl of MTT solution was added to each well 
and the plate was incubated at 37°C for 4 h. The 
resultant formazan product was dissolved by the addi- 
tion of 100/xl of 20% SDS/0.01 N HC1 and vortex- 
ing, and the absorbance was measured on a mi- 
croplate reader at 595 nm test wavelength with the 
reference at 655 nm. 
We prepared SK2 cell-encapsulating APA micro- 
capsules (APA-SK2 cells) the diameters of which 
were 400-600 /xm. The viability of the encapsulated 
SK2 cells was monitored by crushing the APA mi- 
crocapsules and trypan blue extrusion method, and 
over 70% of the APA-SK2 cells remained vital im- 
mediately after the microencapsulation. To examine 
the proliferation of APA-SK2 cells and the secretion 
of SK2 mAb from the APA-SK2 cells, we first 
cultured APA-SK2 cells in vitro and measured those 
profiles after cultivation. APA-SK2 cells continued to 
proliferate and secrete SK2 mAb until day 40 post- 
cultivation, and the viable cell number of APA-SK2 
cells then unfortunately decreased (Fig. 2). On day 
40, the APA microcapsules were still full of SK2 
cells (Fig. 3A), and an electron microscopy study of 
the encapsulated SK2 cells revealed that the struc- 
tural integrity of the cells was maintained when the 
APA membrane was torn off (Fig. 3B). Moreover, it 
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Fig. 1. Protocol of cytomedical therapy for lgG1 plasmacytosis in hlL-6 Tgm. 
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therapeutic effect was superior to that of the injection 
of Aga-SK2 cells, free SK2 cells, and SK2 mAb. The 
spleen weights at 14 weeks of age con'elated with the 
plasma IgG1 level in each group. The hypertrophy of
Cultivation time (Days) 
Fig. 2. Profile of proliferation and SK2 mAb-secretion of APA- 
SK2 cells under tissue culture condition, APA-SK2 cells (1 × 106 
cells per ml of capsules) were cultured in RPMI 1640 medium 
supplemented with 10% FCS at 37°C in 5% CO s in a 100 mm 
culture dish. The culture medium was replaced every two days, 
and the MTT assay was performed on the indicated day. The 
amount of SK2 mAb secreted from 200 /zl of APA-SK2 cells 
was calculated as the concentration of SK2 mAb in conditioned 
medium for 24 h, which was measured with a mouse IgGI-ELISA 
system. Each data point represents the mean_+S.D, for 5-6 
cultures. 
was observed that the APA membrane were about 4 
/zm in dry-wall thickness (Fig. 3C). 
3.2. Therapeutic effects of APA-SK2 cells, Aga-SK2 
cells, ,fiee SK2 cells, and SK2 mAb on lgG1 plasma- 
cytosis in hlL-6 Tgm 
The hIL-6 Tgm of C57BL/6 origin are subject o 
massive IgGl plasmacytosis with age resulting from 
excessive activation of B lymphocytes [40,41]. In 
these hIL-6 Tgm, serum hIL-6 concentrations were 
more than 600 pg/ml  after 6-week old determined by 
the hIL-6-specific ELISA [42] or the MH60 cells-pro- 
liferation assay. We found previously that the injec- 
tion of SK2 mAb in hIL-6 Tgm had therapeutic 
effects (unpublished data). Furthermore, a single in- 
jection of Aga-SK2 cells to the hlL-6 Tgm were 
effective as treatment of the plasmacytosis and 
mesangio-proliferative glomerulonephritis in the hlL- 
6 Tgm [36]. We compared the therapeutic effect of 
i.p. injection of APA-SK2 cells in hlL-6 Tgm with 
that of Aga-SK2 cells, free SK2 cells and SK2 mAb. 
The increase in the plasma IgG1 level with age in 
the hlL-6 Tgm was remarkably suppressed by a 
single injection of APA-SK2 cells (Fig. 4A). This 
Fig. 3. Micrograph of APA microcapsules containing SK2 cells. 
APA-SK2 cells (I X l06 cells per ml of capsules) were cultured 
in RPMI 1640 medium supplemented with 10% FCS at 37°C in 
5% CO 2. APA-SK2 cells were photographed with phase contrast 
microscopy (A) and scanning electron microscopy (B,C) at day 
40 post-microencapsulation. 
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of splenic structure, the red pulp and the white pulp, 
were not distinguishable (Fig. 5A and B). The splenic 
structure, especially the structure of the white pulp, 
remained almost normal in the APA-SK2 cells- (Fig. 
5C) and Aga-SK2 cells- (Fig. 5D) injected hIL-6 
Tgm, although mild (C) or moderate (D) plasmacyto- 
sis was observed in the red pulp. 
3.3. Effect of APA-SK2 cells, Aga-SK2 cells, free SK2 








0 0.5 1 1.5 
Spleen weight (g) 
Fig. 4. Therapeutic effect of APA-SK2 cells, Aga-SK2 cells, free 
SK2 cells, and SK2 mAb on IgG1 plasmacytosis in hlL-6 Tgm. 
Three ml of APA-SK2 cells (5 X 106 cells per ml of capsules) or 
Aga-SK2 cells (1.25x 107 cells per ml of beads) were i.p. 
injected into hlL-6 Tgm at 7 weeks of age. Five hundred /zl of 
free SK2 cells (7.5 X 10 7 cells per ml) were i.p. injected into 
hlL-6 Tgm at 7 weeks of age. SK2 mAb was subcutaneously 
injected to hlL-6 Tgm from 7 weeks to 13 weeks old at the dose 
of 50 /xg/mouse, 3 times/week. A: IgG1 concentration i
plasma. The mouse IgG1 concentration in plasma was measured 
by mouse IgG1-ELISA. (O): Normal mice; (0):  Untreated 
hlL-6 Tgm (control group); (zx): SK2 mAb-injected hlL-6 Tgm; 
([]): Free SK2 cells-injected hlL-6 Tgm; (• ) :  APA-SK2 cells- 
injected hlL-6 Tgm; (A): Aga-SK2 cells-injected hlL-6 Tgm. 
Each data point represents the mean+S.E.M, for 5 mice. B: 
Spleen weight of normal and hlL-6 Tgm at 14 week of age. Each 
value represents the mean___S.D, for 4-6 mice. * P<0.01, 
• * P < 0.001 significantly different from the untreated control 
group. 
the spleen in the hlL-6 Tgm injected with APA-SK2 
cells was significantly suppressed compared to the 
untreated control group, which had spleen weights 
12-fold higher than did the normal mice group (Fig. 
4B). Histological findings revealed severe plasmacy- 
tosis in the spleens of the untreated control group and 
free SK2 cells-treated group. Two major components 
With the reduction of IgG1 plasmacytosis, the 
survival time of hlL-6 Tgm was greatly prolonged by 
the single injection of APA-SK2 cells (Fig. 6). All 
untreated hlL-6 Tgm died within 18 weeks of age, 
whereas all mice in the APA-SK2 cells-treated group 
were alive at 27 weeks. Furthermore, the survival 
times of the APA-SK2 cells-injected group were 
superior to those of the Aga-SK2 cells-injected group, 
the free SK2 cells-injected group and the SK2 mAb- 
injected group. These results suggested that the treat- 
ment of APA-SK2 cells was very effective as treat- 
ment of the hlL-6 Tgm. 
3.4. Growth profile and SK2 mAb-secretion of APA- 
SK2 cells in allogeneic recipients 
To examine how long the APA-SK2 cells injected 
into allogeneic recipient fulfilled their functions, 
APA-SK2 cells injected into allogeneic C57BL/6 
mice were recovered and their MTT activity and SK2 
mAb-secretion were measured in vitro. The serum 
SK2 mAb level in these C57BL/6 mice was also 
measured with the MH60 cells-proliferation assay 
system. This evaluation used C57BL/6 mice as allo- 
geneic recipients instead of hlL-6 Tgm. The MTT 
activity, which showed the viable cell number, and 
the SK2 mAb-secretion of recovered APA-SK2 cells 
increased until day 22 post-injection and then de- 
creased. However, the viable APA-SK2 cells could 
maintained their SK2 mAb productivity (SK2 mAb 
production rate per cell) until the end of culture (Fig. 
7). We also examined the levels of the serum SK2 
mAb in C57BL/6 mice injected with APA-SK2 
cells. The C57BL/6 mice injected with APA-SK2 
cells showed high serum SK2 mAb concentrations; 
the concentrations were 3-5 mg/ml  between day 14 
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Fig. 6. Effect of APA-SK2 cells on survival time of hlL-6 Tgm. 
The treatment of each group was described in Fig. 4. (0): 
Untreated hlL-6 Tgm (control group); (zx): SK2 mAb-injected 
hlL-6 Tgm; (D): Free SK2 cells-injected hlL-6 Tgm; (ll): 






~ ,  . , r'l, . I l -  
l0 20 30 40 50 60 70 80 
Days after injection 
Fig. 8. Concentration of serum SK2 mAb in C57BL/6 mice 
injected with APA-SK2 cells or free SK2 cells. Three ml of 
APA-SK2 cells ( I ,  1 X 10 6 cells per ml of capsules) or 500 /xl 
of free SK2 cells (D, 7.5X 10 7 cells per ml), were intraperi- 
toneally injected into normal C57BL/6 mice at 7 weeks of age. 
The SK2 mAb concentration i  serum was measured by an 
MH60 cells-proliferation assay system. Each data point repre- 
sents the mean_+ S.E.M. for 4 mice. 
and day 50. However,  the SK2 mAb level in serum 
decreased after day 30, which reflected the viable cell 
number and the SK2 mAb-secretion of APA-SK2 
cells, as shown in Fig. 7. In contrast, SK2 mAb in 
serum of C57BL/6  mice injected with free SK2 cells 
was hardly detected (Fig. 8). 
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Fig. 7. Viability and SK2 mAb-secretion of APA-SK2 cells 
injected into allogeneic recipient. Three ml of APA-SK2 cells 
(1 X 10 6 cells per ml of capsules) were i.p. injected into normal 
C57BL/6 mice at 7 weeks of age. APA-SK2 cells were recov- 
ered from these mice on the indicated ays and cultured in RPMI 
1640 medium supplemented with 10% FCS at 37°C in 5% CO 2 
on a 24-well culture plate. Their viability and SK2 mAb-secretion 
were evaluated by MTT assay and mouse IgGI-ELISA system, 
respectively. Each data point represents he mean + S.D. for 3-4 
mice. 
4. D iscuss ion  
Medical applications of immobil ized enzymes, 
called artificial cells, have been established by Chang 
et al. [48-52], who also first proposed the possible 
application of microencapsulation f  intact cells [49]. 
Sun et al. [1-4] demonstrated that islet cells, encapsu- 
lated in an APA membrane, could be restored to 
normoglycemia when transplanted i.p. into diabetic 
animals. Recently, by genetic engineering and cell 
techniques, cell therapy using microencapsulating 
cells which were modified to produce and secrete 
useful biomolecules was attempted for the correction 
of inherited or acquired human disorders by several 
laboratories [26-35]. We have previously demon- 
strated that living cells microencapsulated with 
agarose hydrogel had a potential application as an 
effective long-term delivery system of bioactive drugs 
in vivo, and we called the strategy of this drug 
delivery system cytomedicine [36]. 
In the present study, we demonstrated that APA 
microcapsules with SK2 cells were able to cure IgG1 
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plasmacytosis in hlL-6 Tgm used as the model for 
cytomedical therapy. SK2 cells remained vital and 
maintained the function of SK2 mAb-secretion in 
APA microcapsules (Fig. 2). Thus, the APA mem- 
brane was permeable to nutrients and oxygen, which 
are essential to the cell proliferation, and to cellular 
metabolites and products. Moreover, the in vitro cell 
proliferation and SK2 mAb-secretion of the APA-SK2 
cells were higher than those of the Aga-SK2 cells 
previously reported [36]. The present results strongly 
suggest that APA-SK2 cells can prolong the cy- 
tomedical therapeutic effects against hlL-6 Tgm as 
compared with Aga-SK2 cells. 
IgG1 plasmacytosis, which produces the symptoms 
of the hypertrophy and degeneration f spleen and an 
increase of the plasma IgG1 level, was remarkably 
suppressed by a single injection of APA-SK2 cells 
into 7-week-old hlL-6 Tgm, when these mice had not 
yet shown hematological changes (Figs. 4 and 5). In 
contrast, the increase in the plasma IgG1 level in the 
hlL-6 Tgm injected with free SK2 cells was sup- 
pressed for only 2 weeks. Free SK2 cells would 
remain vital and secrete SK2 mAb for at most 2 
weeks, because those cells would be rejected by the 
host's cellular immune system. The hlL-6 Tgm which 
were subcutaneously injected with SK2 mAb showed 
a low IgG1 level during SK2 mAb administration 
period. However, the plasma IgG1 concentration of
these mice increased after the SK2 mAb injections 
were completed. The survival times of the hlL-6 Tgm 
reflected the increase of IgG1 level in each group 
(Fig. 6). These results suggested that the APA mem- 
brane isolated the inner SK2 cells from the allogeneic 
host's immune system, and that SK2 mAb were 
delivered over a long term from APA-SK2 cells in 
vivo. As we expected, the APA microcapsules had a 
larger space for cell proliferation and gave cells a 
better environment to survive for a long time than did 
agarose microbeads, and the cytomedical therapeutic 
effect of the APA-SK2 cells thus exceeded that of 
Aga-SK2 cells. 
In order to confirm the cell proliferation and the 
SK2 mAb-secreting function of APA-SK2 cells in 
allogeneic recipients, APA-SK2 cells were injected 
into allogeneic normal C57BL/6 mice. The cell pro- 
liferation and the SK2 mAb-secretory function of 
APA-SK2 cells in allogeneic normal C57BL/6 mice 
were expected to reflect the parameters in hlL-6 
Tgm, because the hlL-6 Tgm were derived from 
C57BL/6 mice. The pattern of proliferation and SK2 
mAb-secretion of APA-SK2 cells recovered from the 
C57BL/6 mice correlated well with the in vitro 
results (Figs. 2 and 7), although the growth rate, 
MTT activity and SK2 mAb-secretion of APA-SK2 
cells recovered from the C57BL/6 mice were higher 
than those of APA-SK2 cells cultured in vitro. In 
vivo conditions hould be suitable for the growth of 
SK2 cells, compared with in vitro culture condition, 
because cytokines produced in host might influence 
SK2 hybridoma cells. The profile of the serum SK2 
mAb level in the C57BL/6 mice injected with APA- 
SK2 cells correlated well with that of the in vivo 
viable cell number of APA-SK2 cells (Figs. 7 and 8). 
Because SK2 mAb could not be detected in the mice 
injected with free SK2 cells, this result strongly 
suggests that APA-SK2 cells were immunoisolated in 
the allogeneic host. 
However, although these results demonstrate hat 
the in vivo long-term delivery of SK2 mAb was 
achieved by injection of APA-SK2 cells, the effec- 
tiveness of this system (cytomedicine) proved to have 
a limited duration. This limitation may be due to the 
disappearance of the inner space of the microcapsule 
for cell proliferation, because APA-SK2 cells recov- 
ered from C57BL/6 mice on day 100 post-injection 
showed necrosis and calcification due to overgrowth 
in the microcapsule, although the surface of the 
recovered APA microcapsules was intact and no 
host's inflammatory esponse against APA-SK2 cells 
was observed (data not shown). Almost universal cell 
lines, which proliferate permanently, would not be 
able to remain vital and maintain various functions 
including sensing, signal transduction, biosynthesis 
and controlled release, if the cells lose space for their 
proliferation. Therefore, an alternate strategy for con- 
trolling cell growth in the microcapsule is necessary 
for the development of cytomedicine using universal 
cell lines; for example, utilizing a cell line which is 
sensitive to contact inhibition, the formation of 
spheroids, or induction to terminal differentiation. 
Cell therapy will continue to develop in the forms 
of bioartificial organs, somatic gene therapy and drug 
delivery systems for bioactive molecules. Further e- 
search is necessary, in areas such as analysis of 
various cell functions, creation of useful cell lines 
and identification of better polymers for cell immobi- 
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lization in terms of strength, immunoisolation and 
biocompatibility. More animal models should be 
tested before any application of cytomedicine to hu- 
man disease. The present results indicate that engi- 
neered cells microencapsulated in a biocompatible, 
semipermeable membrane have considerable poten- 
tial for clinical use. 
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